Showing results (561-570 of 615) with videos related to
Sort By:
Pageof 62
Annals of Neurology|December 19, 2019
Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral SclerosisAlbert C Ludolph, Johannes Dorst, Jens Dreyhaupt, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 16, 2023
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and preventionUlrike Leiter, Markus V Heppt, Theresa Steeb, et al.Bone Marrow Transplantation|April 3, 2026
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantationKristina Maas-Bauer, Thomas Meyer, Mehtap Yücel, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 17, 2026
ALS motor phenotypes: a revised 'OPM' classificationThomas Meyer, Nicola Ticozzi, Markus Weber, et al.Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 30, 2021
Caregivers' divergent perspectives on patients' well-being and attitudes towards hastened death in Germany, Poland and SwedenPeter M Andersen, Magdalena Kuźma-Kozakiewicz, Jürgen Keller, et al.Annals of Clinical and Translational Neurology|February 22, 2022
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophyCamilla Binz, Alma Osmanovic, Nele H Thomas, et al.The Lancet. Neurology|June 24, 2018
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trialAlbert C Ludolph, Joachim Schuster, Johannes Dorst, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 20, 2026
Minimum important slowing of disease progression as determined by the ALS functional rating scale - a survey of patient expectations toward disease-modifying drugs in ALSThomas Meyer, André Maier, Torsten Grehl, et al.Journal of the Neurological Sciences|September 5, 2025
The expanding clinical utility of blood neurofilament light chain (bNfL): a multi-disciplinary diagnostic toolPeter Körtvelyessy, Burak Arslan, Jonah Nietiet, et al.Pageof 62